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Abstract
Breast cancer is the most prevalent cancer and the leading cause of cancer-related death among females worldwide. 
Despite all therapeutic advances, metastatic breast cancer is still associated with a median overall survival of 3 years. 
Alongside this condition, bladder metastases of solid neoplasms are rarely observed. In this setting, the secondary bladder 
tumors with an origin in breast cancer occur in 2.5% of cases in some series. The authors report the case of a 68-year-old 
female with stage IV breast cancer (bone metastasis) treated with anastrozole, who presented with peripheral edema 
and renal failure with a creatinine clearance of 12.5 mL/min. After hospital admission, the patient was diagnosed with 
new liver lesions and bladder involvement with bilateral hydronephrosis. She was submitted to bilateral percutaneous 
nephrostomies with improvement in renal function. There was a high suspicion of primary bladder tumor in this patient 
who was a previous smoker, with a family history of high-grade bladder carcinoma (her mother). Liver and transurethral 
biopsies were performed, and histological examination was consistent with breast cancer metastases. The patient started 
treatment with capecitabine and denosumab, remaining clinically stable after 3 months of treatment. This case report 
underlines the diagnostic challenges of bladder metastases in a patient with multiple risk factors for bladder cancer and 
without evident clinical symptoms. Even though this is a rare entity, the close surveillance of metastatic breast cancer is 
important in order to allow early detection of new metastatic sites and their treatment to preserve the quality of life in 
these patients. 
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INTRODUCTION
In 2018, worldwide, breast cancer presented an 
estimated age-standardized incidence and mortality of 
46.3 and 13.0 per 100,000 inhabitants, respectively.1 
Breast cancer is the most prevalent cancer and the 
leading cause of cancer-related death in females 
across the globe. Despite all the recent therapeutic 
advances, metastatic breast cancer is still associated 
with poor prognosis with a median overall survival of 
3 years, and a 5-year survival rate of approximately 
25%.2 Metastatic disease at the time of the initial 
diagnosis is not common in breast cancer, with an 
estimated prevalence of 6%.3 The different breast 
cancer subtypes have been associated with different 
patterns of metastatic disease. The most frequent 
locations of breast cancer metastatic disease are the 
bone, liver, and lung.4,5 In this clinical case, we present 
a rare form of presentation of metastatic breast cancer.
CASE REPORT
A 68-year-old female patient sought the 
emergency room complaining of a 4-day history of 
back pain radiating to the flank, which she associated 
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with physical effort. Her past medical history included 
the diagnosis of rheumatoid arthritis, congestive 
heart failure with preserved ventricular function, 
and smoking (40 pack/years). She had undergone 
a mammogram every 2 years integrated into the 
national breast cancer screening scheme. Her living 
brother was diagnosed with Hodgkin lymphoma, and 
her mother, who had high-grade bladder urothelial 
carcinoma, had died at the age of 86. The diagnostic 
work-up included a spine computed tomography (CT) 
scan that showed diffuse morphologic and structural 
changes involving the posterior bodies and arches 
of the sacroiliac vertebrae with lithic lesions and 
discrete cortical erosions consistent with metastases. 
The thoracic, abdominal, and pelvic CT scan showed 
pleural effusion plus cervical and axillary adenopathy. 
The pleural effusion was consistent with transudate by 
biochemical analysis. The histological examination of 
the biopsied cervical lymph node was consistent with 
metastasis of breast cancer with positivity for CK7, 
CK19, CK20, E-cadherin, and estrogen receptors, but 
negativity for progesterone receptors and c-ErbB2. 
The ultrasound and mammography failed to show the 
primary breast cancer lesion. The patient was started 
on anastrozole and denosumab, and the disease 
remained stable for 17 months. By that time, she had 
started presenting peripheral edema and asthenia, but 
no concomitant urinary complaints such as dysuria, 
hematuria, or decreased urinary output. The analytic 
evaluation showed renal failure with creatinine 
clearance of 12.5 mL/min, hypocalcemia, and elevation 
of the tumoral marker Ca15.3 of 93 U/mL (previously 
61 U/mL; reference range <30 U/mL). The physical 
examination was normal except for the presence of 
lower limbs edema without other significant changes. 
The urinary tract ultrasound showed a vesical mass with 
5 × 1.5cm and signs of invasion of both orifices of the 
ureters with consequent bilateral hydronephrosis. She 
was submitted to bilateral percutaneous nephrostomies 
with improvement in the renal function. The pelvic CT 
scan revealed a 5 cm lesion in the bladder floor (making 
it difficult to establish a cleavage plane with the vaginal 
dome), and multiple hepatic nodules consistent with 
metastases (Figure 1).
Due to the suspicion of bladder urothelial 
carcinoma, a liver biopsy and transurethral resection 
(RTU-V) of the bladder lesion were performed. During 
the RTU-V, both orifices of the ureters were not 
found due to the tumor invasion, and the lesion was 
partially resected. Histologic analysis of the liver biopsy 
was consistent with breast cancer metastasis with 
diffuse marking to CK7, estrogen, and progesterone 
receptors; and negative for CK20, CDX-2, TTF-1, 
c-ErbB2, and uroplakin III. Histologic analysis of the 
bladder biopsy showed tissue with the representation 
of mucosa, submucosa, and muscular tunica with 
neoplastic infiltration. The immunohistochemical study 
was characterized by the diffuse expression for CK7, 
estrogen receptors, and GATA3; and negative for 
CK20, p40 and uroplakin III, consistent with metastatic 
involvement of primary breast cancer (Figures 2 and 3).
The patient started treatment with capecitabine 
and denosumab, and remains clinically stable after 
3 months of treatment with a decrease of the tumoral 
marker Ca15.3 to 72 (previously 93).
Figure 1. Computed tomography scan. A – Infiltrative lesion of the bladder floor, making it difficult to establish 
a cleavage plane with the vaginal dome, and infiltrating both orifices of the ureters. B – Bilateral hydronephrosis.
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Figure 2. Photomicrographs of the biopsy specimen. A – Preserved urothelial mucosa (on the right) and mucosa 
involved by the neoplasm (on the left), with extensive involvement of the chorion by sheets or small nests of bulky 
neoplastic cells (H&E, 10X). B – Intense and diffuse expression of cytokeratin 7 by the neoplastic cell population 
on the left (10X). C – Intense and diffuse expression of GATA3 by the neoplastic cell population on the left (10X). 
D – Intense and diffuse expression of the estrogen receptors by the neoplastic cell population, and the absence of 
the ER expression by the residual surface urothelium (10X).
Figure 3. Immunohistochemical photomicrographs of negative staining for uroplakin III in a collection of neoplastic 
cells. A – Liver biopsy. B – Bladder biopsy.
DISCUSSION
Occult breast cancer is extremely rare, accounting 
for 0.2% to 0.9% of all breast cancer cases.6,7 It presents 
without a detectable primary cancer lesion whether on 
a physical examination or an imaging examination such 
as ultrasound and mammograph. The initial symptoms 
of this entity include axillary lymph node metastasis, 
distant metastasis, nipple discharge, nipple dermatitis, 
papillary dermal edema, eczema, and skin retraction.8
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The low incidence of occult breast cancer poses 
a diagnostic and therapeutic challenge even with 
the increasing availability of investigative techniques, 
such as mammography, ultrasound, and magnetic 
resonance imaging (MRI).9,10 MRI and mammography 
can be used to detect non-occult breast cancer, but 
they are not sensitive for the diagnosis of occult 
breast cancer cases.11 However, immunohistochemical 
staining of tumor tissue using breast-cancer-specific 
glycoprotein monoclonal antibodies is widely used 
for the diagnostic and prognostic evaluation of breast 
cancer.12
Particularly in this case, immunohistochemistry 
of the cervical lymph node biopsy pointed to breast 
origin, except for the expression of CK20, which may 
be an error. However, the lymph node biopsy could not 
be re-evaluated because it was processed in another 
laboratory.
Bladder secondary tumors from solid cancer are 
a rare entity. The retrospective study of Bates and 
Baithun13 revealed that secondary tumors comprised 
2.3% of surgical and 20% of postmortem cases in 
a series comprising 6,289 bladder tumors with the 
estimated prevalence of bladder secondary tumors of 
4.5%. Most of the cases of bladder secondary tumors 
had their origin in adjacent organs as a direct invasion. 
The most common primary sites are the female genital 
tract, the prostate, and the lower gastrointestinal tract. 
Lymphatic or hematogenous metastatic spread to the 
bladder from distant primary tumors does occur but 
is much less common. In this setting, primary tumors 
of the stomach, skin, and lung are the most common 
places of origin of these distant metastases.13 A recent 
systematic review conducted by Sanguedolce et al.14 
reported 54 cases of breast cancer with bladder 
metastasis. A retrospective study with 282 cases of 
secondary solid bladder tumors showed a prevalence 
of 2.5% of breast cancer metastasis.13 Also, the 
analyses by Abrams et al.15 found the incidence of 
3.6% of secondary tumors of the bladder in a series 
of 1,000 autopsies of malignant epithelial neoplasms, 
and 4 cases (2.4%) of secondary bladder involvement 
with the origin in breast carcinoma. On the other 
hand, a study comprising 43 autopsies on patients 
with primary carcinoma of the breast did not find any 
case of bladder involvement.16
The metastatic involvement of the bladder may 
present a broad spectrum of symptoms; namely 
dysuria, urgency, lower abdominal or flank pain, and 
gross or microscopic haematuria.17,18 Less frequently, 
patients may be asymptomatic. The acute renal failure 
due to ureteral obstruction with hydronephrosis is a 
rare complication due to metastatic breast cancer.19,20 
Winston et al.21 conducted a retrospective review 
of 57 CT scans of patients with metastatic lobular 
breast cancer and identified 6 patients (11%) with 
hydronephrosis as a complication caused by inﬁltration 
of the retroperitoneum.
In this specific case, the patient presented with 
peripheral edema and asthenia, secondary to renal 
failure due to hydronephrosis caused by a vesical 
mass. Further study showed hepatic nodules as well. 
Both the vesical mass and a hepatic nodule were 
biopsied, and both biopsies were consistent with the 
diagnosis of breast cancer metastasis, as was evident 
in the immunohistochemical analysis: CK7, estrogen, 
and progesterone receptors; and negative for CK20, 
CDX-2, TTF-1, c-ErbB2, and uroplakin III for the hepatic 
biopsy and diffuse expression for CK7, estrogen 
receptors, and GATA3; and negative for CK20, p40, 
and uroplakin III for the vesical biopsy. The absence 
of simultaneous staining for CK7 and CK20, which is 
typical in 65% cases of urothelial carcinomas, positive 
staining for estrogen receptors and negative staining 
for uroplakin III confirmed the diagnosis of liver and 
bladder metastasis of breast cancer.
The treatment of metastatic breast cancer may 
comprise a combination of chemotherapy and hormonal 
treatment depending on the intrinsic characteristics of 
the tumor and its clinical features. The transurethral 
resection of the lesion may improve symptomatology 
and allow catheterization of the ureters. However, in 
some cases, percutaneous nephrostomy is needed, as 
it was in our case report. Radiotherapy has its role as 
a hemostatic measure and as a local disease control.
The patients with bladder metastases usually 
have other metastatic sites and tend to have a poor 
prognosis.22
Our case exemplifies a rare form of metastatic 
breast cancer. The presence of risk factors, such as 
smoking tobacco, a family history of bladder cancer 
along with a failure of imaging study, and a lack of 
clinical symptoms, challenged the diagnosis of our 
case. It is essential for clinicians to be aware of urinary 
symptoms in breast cancer patients, as well as the early 
recognition of disease progression, and the necessity 
of rapid institution of measures to preserve the quality 
of life in these patients.
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